{"id":"W4386152079","doi":"10.1002/cncr.34987","title":"Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial","year":2023,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK; Seagen; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Pharmacyclics; Genentech; Legend Biotech; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Adverse effect; Clinical endpoint; Anemia; Gastroenterology; Quality of life (healthcare); Clinical trial; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004112098,0.001060896,0.002233152,0.0002758958,0.000254426,0.001329525,0.0008693998,0.000716516,0.002158293],"category_scores_gemma":[0.001710871,0.0003805705,0.002557701,0.0003890818,0.0004482633,0.0007472984,0.0005232819,0.001717846,0.0005877388],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001209104,"about_ca_system_score_gemma":0.001466545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009496083,"about_ca_topic_score_gemma":0.003387334,"domain_scores_codex":[0.998903,0.0006722289,0.0000532152,0.0001443374,0.0001093493,0.0001178724],"domain_scores_gemma":[0.9991403,0.0001676308,0.0002102285,0.00009253251,0.00007194354,0.0003173526],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8959765,0.00429723,0.01127492,0.001213073,0.006989763,0.0001560761,0.0001815923,0.00295984,0.006926056,0.0003156652,0.007335594,0.06237361],"study_design_scores_gemma":[0.8759448,0.07615282,0.03212693,0.000148666,0.00399791,0.0003937088,0.00008432268,0.002263959,0.001332735,0.0004844233,0.00700606,0.0000636872],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.976346,0.01220157,0.0006234734,0.001200501,0.0001817156,0.0013893,0.004580866,0.0001272052,0.003349476],"genre_scores_gemma":[0.9800792,0.002891378,0.001755632,0.00123211,0.000191036,0.001510342,0.01009275,0.00004995348,0.002197508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004112098,"threshold_uncertainty_score":0.02174711,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04513348790059476,"score_gpt":0.3060874820950584,"score_spread":0.2609539941944636,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}